Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Exclusive Article
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income, which makes its recent performance all the more striking. Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has raised questions about whether the foundation of this industry leader is cracking.
In the late 1960s, Xerox fell 71%, Avon dropped 86%, and Polaroid collapsed 91% — while a completely different group of overlooked stocks delivered gains as high as 2,300%. JC Parets has traced this pattern back 135 years, and he says the same market split is forming right now.
He just recorded a short briefing showing which side of the divide he's positioned on — and he's giving away one stock name free. Watch JC's urgent briefing here
A deeper look reveals a potential disconnect between market sentiment and operational reality. The critical question: is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseAbbott's recent decline reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven mainly by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan: CEO Robert B. Ford described price and promotion actions plus a pipeline of at least eight new product launches in 2026 aimed at reigniting volume growth, with a return to growth expected in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant capital rotation. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broader trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment navigates a short-term recovery, Abbott's core remains strong, driven by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s overall health is most apparent in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical-care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. The product line—allowing users to track glucose levels without routine fingersticks—generated more than $7.5 billion in sales in 2025 and remains a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit pace, while Structural Heart posted strong organic growth of 8.7%. This strength comes from a portfolio of best-in-class products, such as MitraClip and TriClip, and a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also moving to secure future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. That deal would position Abbott in the rapidly expanding market for cancer diagnostics, adding a high-growth vertical likely to contribute meaningfully to revenue over time. That bullish view is shared by Wall Street. Analysts maintain a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying more than 30% upside from current levels and signaling a belief that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is particularly compelling. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years—evidence of a deep-seated commitment to returning capital through all market cycles. The recent decline in Abbott’s stock price benefits new investors by boosting the dividend yield to about 2.5% at current levels. The dividend appears well supported: it represents roughly 68% of reported earnings but only about 37% of operating cash flow, indicating that Abbott generates more than enough cash to cover payments with room to maintain or raise the payout in the future. A Disconnect Between Price and ValueCurrent market sentiment around Abbott seems disconnected from the company's operational fundamentals. Temporary headwinds in a single division and a broad market rotation have depressed the stock price, yet Abbott's core growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a reliable income source, and strategic moves such as the Exact Sciences acquisition provide clear catalysts. For investors with a long-term horizon, the present valuation suggests a meaningful gap between market price and fundamental value—an opportunity worth considering. |
